Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Updated CLL guidelines

Hallek M et al. Blood https://doi.org/10.1182/blood-2017-09-806398

Publish date:: April 6, 2018

Major changes or additions to new guidelines for chronic lymphocytic leukemia include the following:

Molecular genetics: Recognition of the clinical importance of specific genomic alterations/mutations 17p deletion and mutations in TP53 on therapeutic response.

IGHV mutational status: Immunoglobulin variable heavy chain (IGHV) genes offer important prognostic information.

Biomarkers: Soluble CD23, thymidine kinase, and beta-2-microglobulin need to be standardized and used in prospective clinical trials.

MRD: Minimal residual disease should be assessed in clinical trials aimed at maximizing remission depth.

Antiviral prophylaxis: Patients should be tested for HBV serological status before starting on an anti-CD20 agent.

Read the article.

Citation:

Hallek M et al. Blood https://doi.org/10.1182/blood-2017-09-806398

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,